PriceTargets.com logo

NASDAQ:DOVA - Dova Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$28.04 As of 11/12/2019 01:00 AM ET
+0.30 (1.20%)
Get New Dova Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DOVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DOVA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Dova Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $28.04.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Dova Pharmaceuticals. This rating has held steady since October 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/7/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/6/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/5/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/4/2019WedbushDowngradeOutperform ➝ Neutral$24.00 ➝ $29.00Low
i
Rating by L. Chico at Wedbush
10/3/2019LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$32.00 ➝ $29.00Low
i
10/3/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$16.00 ➝ $28.00Low
i
9/30/2019HC WainwrightDowngradeBuy ➝ Neutral$45.00 ➝ $27.50Medium
i
Rating by Joseph Pantginis at HC Wainwright
9/19/2019HC WainwrightBoost Price TargetBuy$39.00 ➝ $45.00High
i
Rating by Joseph Pantginis at HC Wainwright
8/29/2019OppenheimerInitiated CoverageOutperform$30.00 ➝ $30.00Medium
i
7/12/2019JPMorgan Chase & Co.Boost Price TargetUnderweight$13.00 ➝ $15.00Low
i
7/1/2019Evercore ISIUpgradeIn-Line ➝ Outperform$15.00High
i
6/27/2019HC WainwrightBoost Price TargetBuy$18.00 ➝ $39.00High
i
Rating by Joseph Pantginis at HC Wainwright
5/22/2019WedbushInitiated CoverageOutperform ➝ Outperform$19.00High
i
Rating by L. Chico at Wedbush
4/26/2019HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Joseph Pantginis at HC Wainwright
3/5/2019HC WainwrightSet Price TargetBuy$18.00High
i
Rating by Joseph Pantginis at HC Wainwright
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$34.00 ➝ $20.00Low
i
12/20/2018HC WainwrightInitiated CoverageBuy ➝ Buy$18.00Low
i
Rating by J. Pantginis at HC Wainwright
12/18/2018LADENBURG THALM/SH SHBoost Price TargetBuy$32.00High
i
9/4/2018SVB LeerinkLower Price TargetMarket Perform ➝ Market Perform$32.00 ➝ $31.00Low
i
Rating by G. Porges at SVB Leerink LLC
8/29/2018Raymond JamesInitiated CoverageOutperform ➝ Outperform$44.00Medium
i
7/15/2018Jefferies Financial GroupReiterated RatingBuy$40.00Low
i
7/9/2018SVB LeerinkDowngradeOutperform ➝ Market PerformHigh
i
Rating by G. Porges at SVB Leerink LLC
4/26/2018LADENBURG THALM/SH SHInitiated CoverageBuyHigh
i
3/23/2018Evercore ISIInitiated CoverageIn ➝ line$29.00High
i
11/28/2017Jefferies Financial GroupBoost Price TargetBuy$33.00High
i
9/26/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$32.00High
i
Rating by G. Porges at SVB Leerink LLC
7/24/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$35.00High
i
7/24/2017SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$24.00High
i
Rating by G. Porges at SVB Leerink LLC
7/24/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$30.00Medium
i
(Data available from 2/28/2016 forward)
Dova Pharmaceuticals logo
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $28.04
$28.04
$28.04

50 Day Range

MA: $28.04
$28.04
$28.04

52 Week Range

Now: $28.04
$5.62
$28.54

Volume

35,036 shs

Average Volume

499,313 shs

Market Capitalization

$807.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Dova Pharmaceuticals?

The following sell-side analysts have issued reports on Dova Pharmaceuticals in the last twelve months:
View the latest analyst ratings for DOVA.

What is the current price target for Dova Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Dova Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Dova Pharmaceuticals in the next year.
View the latest price targets for DOVA.

What is the current consensus analyst rating for Dova Pharmaceuticals?

Dova Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DOVA.

What other companies compete with Dova Pharmaceuticals?

Other companies that are similar to Dova Pharmaceuticals include Amicus Therapeutics, Pacira BioSciences, Rocket Pharmaceuticals, Alkermes, OPKO Health, ALX Oncology, Corcept Therapeutics, Viela Bio, Intra-Cellular Therapies, Xencor, Taro Pharmaceutical Industries, Prelude Therapeutics, IGM Biosciences, Global Blood Therapeutics and Amarin.

How do I contact Dova Pharmaceuticals' investor relations team?

Dova Pharmaceuticals' physical mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company's listed phone number is 919-748-5975 and its investor relations email address is [email protected] The official website for Dova Pharmaceuticals is www.dova.com.